-
EP4121009
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4121009
| EP4121009 - FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 23.12.2022 Database last updated on 14.11.2024 | |
| Former | The international publication has been made Status updated on 08.06.2022 | Most recent event Tooltip | 11.10.2024 | Amendment by applicant | Applicant(s) | For all designated states Zydus Lifesciences Limited Zydus Corporate Park, Scheme No. 63 Survey No. 536, Khoraj (Gandhinagar) Nr. Vaishnodevi Circle Sarkhej - Gandhinagar, Highway, Gujarat Ahmedabad 382481 / IN | [2023/04] | Inventor(s) | 01 /
KANNAN, M. E. ZYDUS LIFESCIENCES LIMITED, Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj ( Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat 382481 / IN | 02 /
LADDHA, Ritu ZYDUS LIFESCIENCES LIMITED, Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj ( Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat 382481 / IN | 03 /
UKAWALA, Mukesh ZYDUS LIFESCIENCES LIMITED, Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj ( Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat 382481 / IN | 04 /
PATEL, Jitendra ZYDUS LIFESCIENCES LIMITED, Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj ( Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat 382481 / IN | 05 /
PRAJAPATI, Amit ZYDUS LIFESCIENCES LIMITED, Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj ( Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat 382481 / IN | [2023/04] | Representative(s) | Bassil, Nicholas Charles, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2023/04] | Application number, filing date | 21772429.3 | 17.03.2021 | [2023/04] | WO2021IB52214 | Priority number, date | IN202021011431 | 17.03.2020 Original published format: IN202021011431 | [2023/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021186356 | Date: | 23.09.2021 | Language: | EN | [2021/38] | Type: | A1 Application with search report | No.: | EP4121009 | Date: | 25.01.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.09.2021 takes the place of the publication of the European patent application. | [2023/04] | Search report(s) | International search report - published on: | IN | 23.09.2021 | (Supplementary) European search report - dispatched on: | EP | 19.03.2024 | Classification | IPC: | A61K9/00, C07D471/04, C07D215/58, A61K9/20, A61K9/48 | [2024/16] | CPC: |
A61K9/2054 (EP,US);
A61K31/4709 (US);
A61K9/2009 (EP,US);
A61K9/2013 (EP,US);
A61K9/2018 (EP);
A61K9/2027 (EP,US);
A61K9/2059 (EP);
A61K9/2077 (EP);
A61K9/2813 (US);
A61K9/2853 (US);
A61K9/2866 (US);
A61K9/4825 (US);
A61K9/485 (EP,US);
A61K9/4858 (EP,US);
A61K9/4866 (EP,US);
C07D215/58 (EP)
(-)
|
| Former IPC [2023/04] | A61K9/00, C07D471/04, C07D215/58 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/04] | Title | German: | FORMULIERUNG MIT HIF-PROLYLHYDROXYLASE-HEMMERN | [2023/04] | English: | FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS | [2023/04] | French: | FORMULATION COMPRENANT DES INHIBITEURS DE HIF PROLYL HYDROXYLASE | [2023/04] | Entry into regional phase | 30.09.2022 | National basic fee paid | 30.09.2022 | Search fee paid | 30.09.2022 | Designation fee(s) paid | 30.09.2022 | Examination fee paid | Examination procedure | 30.09.2022 | Examination requested [2023/04] | 09.10.2024 | Amendment by applicant (claims and/or description) | 09.10.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 30.09.2022 | Renewal fee patent year 03 | 23.01.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [E]WO2021181360 (CADILA HEALTHCARE LTD [IN]); | International search | [Y]WO2007115315 (FIBROGEN INC [US], et al) [Y] 1-19 * the whole document, particularly claims 31-32; page 33, lines 1-15 *; | [Y]WO2014014835 (FIBROGEN INC [US]) [Y] 1-19* the whole document, particularly abstract, claim 55, para 0069 *; | [XY]WO2014102818 (CADILA HEALTHCARE LTD [IN]) [X] 1-2 * the whole document, particularly Abstract, claim 9 claims 1-9 * [Y] 3-19; | [Y]WO2014197660 (FIBROGEN INC [US]) [Y] 1-19 * the whole document, particularly claims 35, 51-57; para 0091, 0093, 0095 *; | [Y]WO2014200773 (AKEBIA THERAPEUTICS INC [US]) [Y] 1-19 * the whole document, particularly claims 106-108; para 00312-00323 *; | [Y]WO2016049097 (MERCK SHARP & DOHME [US], et al) [Y] 1-19 * the whole document, particularly abstract, claim 6; page 20 lines 20-25 * |